Press Release ·
IMGENEX India awarded BIRAC Phase II grant to develop biosimilar Herceptin for breast cancer
IMGENEX India received a 3-year Phase II grant under the BIRAC scheme of the Government of India to develop biosimilar Herceptin (Trastuzumab) for the treatment of breast cancer.
IMGENEX India has been awarded a 3-year Phase II grant under the BIRAC scheme, Government of India, to develop biosimilar Herceptin (Trastuzumab) for the treatment of HER2-positive breast cancer. The grant supports bioprocess development and scale-up of the biosimilar candidate using IMGENEX India's proprietary high-yield CHO mammalian expression platform.